[抗体对阿尔茨海默病治疗有优势吗？索拉珠单抗：尚无定论] - Suppr

Suppr

超能文献

[Do antibodies provide advantages for the therapy of Alzheimer's disease? Solanezumab: the jury is still out].

作者信息

Peters Oliver

出版信息

Dtsch Med Wochenschr. 2014 Mar;139(10):468. doi: 10.1055/s-0033-1353892. Epub 2014 Feb 25.

DOI:10.1055/s-0033-1353892

PMID:24570189

Abstract

摘要

相似文献

[Do antibodies provide advantages for the therapy of Alzheimer's disease? Solanezumab: the jury is still out].

Dtsch Med Wochenschr. 2014 Mar;139(10):468. doi: 10.1055/s-0033-1353892. Epub 2014 Feb 25.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

N Engl J Med. 2014 Apr 10;370(15):1460. doi: 10.1056/NEJMc1402193.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

N Engl J Med. 2014 Apr 10;370(15):1459-60. doi: 10.1056/NEJMc1402193.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

N Engl J Med. 2014 Apr 10;370(15):1459. doi: 10.1056/NEJMc1402193.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

N Engl J Med. 2014 Apr 10;370(15):1460. doi: 10.1056/NEJMc1402193.

Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.

Expert Rev Clin Immunol. 2012 Feb;8(2):135-49. doi: 10.1586/eci.11.93.

[Immunotherapy for Alzheimer's disease].

Ugeskr Laeger. 2016 Jan 18;178(3):V07150588.

Antiamyloid therapy for Alzheimer's disease--are we on the right road?

N Engl J Med. 2014 Jan 23;370(4):377-8. doi: 10.1056/NEJMe1313943.

Solanezumab and the amyloid hypothesis for Alzheimer's disease.

BMJ. 2016 Dec 29;355:i6771. doi: 10.1136/bmj.i6771.

Sixty seconds on . . . solanezumab.

BMJ. 2016 Nov 29;355:i6389. doi: 10.1136/bmj.i6389.

引用本文的文献

, and Genetic Polymorphisms and Antidepressant Response Phenotypes: Results from a Portuguese Major Depressive Disorder Cohort.

Int J Mol Sci. 2024 May 8;25(10):5112. doi: 10.3390/ijms25105112.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

[Do antibodies provide advantages for the therapy of Alzheimer's disease? Solanezumab: the jury is still out].

作者信息

Peters Oliver

出版信息

Dtsch Med Wochenschr. 2014 Mar;139(10):468. doi: 10.1055/s-0033-1353892. Epub 2014 Feb 25.

DOI:10.1055/s-0033-1353892

PMID:24570189

Abstract

摘要

相似文献

[Do antibodies provide advantages for the therapy of Alzheimer's disease? Solanezumab: the jury is still out].

Dtsch Med Wochenschr. 2014 Mar;139(10):468. doi: 10.1055/s-0033-1353892. Epub 2014 Feb 25.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

N Engl J Med. 2014 Apr 10;370(15):1460. doi: 10.1056/NEJMc1402193.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

N Engl J Med. 2014 Apr 10;370(15):1459-60. doi: 10.1056/NEJMc1402193.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

N Engl J Med. 2014 Apr 10;370(15):1459. doi: 10.1056/NEJMc1402193.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

N Engl J Med. 2014 Apr 10;370(15):1460. doi: 10.1056/NEJMc1402193.

Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.

Expert Rev Clin Immunol. 2012 Feb;8(2):135-49. doi: 10.1586/eci.11.93.

[Immunotherapy for Alzheimer's disease].

Ugeskr Laeger. 2016 Jan 18;178(3):V07150588.

Antiamyloid therapy for Alzheimer's disease--are we on the right road?

N Engl J Med. 2014 Jan 23;370(4):377-8. doi: 10.1056/NEJMe1313943.

Solanezumab and the amyloid hypothesis for Alzheimer's disease.

BMJ. 2016 Dec 29;355:i6771. doi: 10.1136/bmj.i6771.

Sixty seconds on . . . solanezumab.

BMJ. 2016 Nov 29;355:i6389. doi: 10.1136/bmj.i6389.

引用本文的文献

, and Genetic Polymorphisms and Antidepressant Response Phenotypes: Results from a Portuguese Major Depressive Disorder Cohort.

Int J Mol Sci. 2024 May 8;25(10):5112. doi: 10.3390/ijms25105112.